カテゴリ： GlobalData, アメリカ, 企業調査

Trovagene Inc (TROV)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Trovagene Inc (TROV) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011968
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：81
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests that provide important clinical information about mutations associated with common solid tumor cancers such as colorectal, melanoma, pancreas and lung cancer. These tests are used by physicians, third party clinical laboratories and pharmaceutical companies. Trovagene uses its proprietary Precision Cancer Monitoring (PCM) technology to detect and monitor circulating tumor DNA (ctDNA) in urine and blood for the detection and quantitation of oncogene mutations and improvement in cancer care. Trovagene is headquartered in San Diego, California, the US.

Trovagene Inc (TROV) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trovagene Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Trovagene Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Trovagene Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Trovagene Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Trovagene Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Trovagene Inc, Medical Equipment, Deal Details 12
Asset Purchase 12
TrovaGene Completes Acquisition Of CLIA-Certified Lab From MultiGEN Diagnostics 12
Trovagene Acquired Hybridoma Monoclonal Antibody Targeting the NPM1 Biomarker 14
Venture Financing 15
TrovaGene Secures USD15 Million in Venture Funding 15
Partnerships 16
Trovagene Enters Into Licensing Agreement with GenSignia IP 16
Trovagene Enters Into Licensing Agreement With Strand Life Sciences For HPV Test 17
TrovaGene Enters into License Agreement for Hairy Cell Leukemia Biomarkers 18
TrovaGene Enters into License Agreement for Chronic Lymphoblastic Leukemia 19
TrovaGene Enters Into Licensing Agreement With Brunangelo Falini 20
Trovagene Enters into Licensing Agreement with Fairview Health Services 21
Trovagene Enters into Licensing Agreement with MLL Munchner Leukamielabor 22
Trovagene Enters into Agreement with Novogene 23
Trovagene Enters into Agreement for Trovera 24
Trovagene Enters into Agreement with AstraZeneca 25
Trovagene Enter into Agreements for Trovera 26
Trovagene Enters into Agreement with Boreal Genomics 27
Trovagene Enters into Agreement with USC Norris Comprehensive Cancer Center 28
Trovagene Enters into Research Agreement with University of Michigan Comprehensive Cancer Center 29
TrovaGene Enters Into R&D Agreement With PerkinElmer Health Sciences 30
Trovagene Enters into Patent Option Agreement with Massachusetts Institute of Technology 31
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 32
Equity Offering 33
Trovagene Files Registration Statement to Raise up to USD17.5 Million in Public Offering of Shares 33
Trovagene Plans to Raise Funds through Public Offering of Shares upon Exercise of Warrants 34
Trovagene to Raise USD7 Million in Private Placement of Shares and Warrants 35
Trovagene Raises USD40.3 Million in Public Offering of Shares 36
Trovagene Completes Public Offering of Shares for USD23 Million 38
Trovagene Completes Private Placement Of Shares For US$15 Million 39
Trovagene Completes Private Placement Of Units For US$4 Million 40
Trovagene Completes Exercise Of Underwriters’ Option For Public Offering Of Units For US$10.6 Million 41
Trovagene Inc – Key Competitors 42
Trovagene Inc – Key Employees 43
Trovagene Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Strategy And Business Planning 45
Aug 18, 2016: Blue Cross Blue Shield Illinois to cover Trovera liquid biopsy tests 45
Feb 22, 2016: Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network 46
Feb 01, 2016: Trovagene Enters into Agreement with FedMed and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform 47
Jan 21, 2016: Trovagene Announces Agreement with America’s Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform 48
Financial Announcements 49
Nov 09, 2017: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 49
Aug 09, 2017: Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results 51
May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 53
Mar 15, 2017: Trovagene Reports Fourth Quarter and Year End 2016 Financial Results 55
Nov 09, 2016: Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments 56
Aug 04, 2016: Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments 58
May 10, 2016: Trovagene Announces First Quarter 2016 Financial Results 59
Mar 10, 2016: Trovagene Announces Fourth Quarter and Year End 2015 Financial Results 61
Corporate Communications 63
Sep 20, 2017: Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis 63
Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 64
Apr 25, 2016: Trovagene Appoints Bill Welch as Chief Executive Officer 66
Mar 28, 2016: Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause 67
Legal and Regulatory 68
Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 68
Product News 69
Sep 09, 2016: Trovagene to Present at the 3rd Annual Precision Medicine Congress 69
May 19, 2016: Large Clinical Data Set in Lung Cancer Featuring Trovagene’s Precision Cancer Monitoring Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting 70
Mar 24, 2016: Clinical Study Results Featuring Trovagene’s Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 71
Mar 08, 2016: Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene’s Precision Cancer Monitoring Platform 72
Other Significant Developments 73
Jul 12, 2017: Trovagene Announces Agreement with Novogene for NextCollect in China 73
Jun 22, 2017: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials 74
Jan 12, 2017: Trovagene Announces Broadening Network of Commercial Distributors 75
Dec 13, 2016: Trovagene announces a reorganization to accelerate global distribution of liquid biopsy technology 76
Aug 17, 2016: BCBS Illinois expands patient access to Trovera tests for 8.1 million covered lives 77
Apr 11, 2016: Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network 78
Mar 01, 2016: Trovagene Enters Into Preferred Provider Agreement with Multiplan 79
Feb 24, 2016: Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
Trovagene Inc, Medical Equipment, Key Facts, 2016 2
Trovagene Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Trovagene Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Trovagene Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Trovagene Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Trovagene Inc, Deals By Market, 2011 to YTD 2017 9
Trovagene Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
TrovaGene Completes Acquisition Of CLIA-Certified Lab From MultiGEN Diagnostics 12
Trovagene Acquired Hybridoma Monoclonal Antibody Targeting the NPM1 Biomarker 14
TrovaGene Secures USD15 Million in Venture Funding 15
Trovagene Enters Into Licensing Agreement with GenSignia IP 16
Trovagene Enters Into Licensing Agreement With Strand Life Sciences For HPV Test 17
TrovaGene Enters into License Agreement for Hairy Cell Leukemia Biomarkers 18
TrovaGene Enters into License Agreement for Chronic Lymphoblastic Leukemia 19
TrovaGene Enters Into Licensing Agreement With Brunangelo Falini 20
Trovagene Enters into Licensing Agreement with Fairview Health Services 21
Trovagene Enters into Licensing Agreement with MLL Munchner Leukamielabor 22
Trovagene Enters into Agreement with Novogene 23
Trovagene Enters into Agreement for Trovera 24
Trovagene Enters into Agreement with AstraZeneca 25
Trovagene Enter into Agreements for Trovera 26
Trovagene Enters into Agreement with Boreal Genomics 27
Trovagene Enters into Agreement with USC Norris Comprehensive Cancer Center 28
Trovagene Enters into Research Agreement with University of Michigan Comprehensive Cancer Center 29
TrovaGene Enters Into R&D Agreement With PerkinElmer Health Sciences 30
Trovagene Enters into Patent Option Agreement with Massachusetts Institute of Technology 31
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 32
Trovagene Files Registration Statement to Raise up to USD17.5 Million in Public Offering of Shares 33
Trovagene Plans to Raise Funds through Public Offering of Shares upon Exercise of Warrants 34
Trovagene to Raise USD7 Million in Private Placement of Shares and Warrants 35
Trovagene Raises USD40.3 Million in Public Offering of Shares 36
Trovagene Completes Public Offering of Shares for USD23 Million 38
Trovagene Completes Private Placement Of Shares For US$15 Million 39
Trovagene Completes Private Placement Of Units For US$4 Million 40
Trovagene Completes Exercise Of Underwriters' Option For Public Offering Of Units For US$10.6 Million 41
Trovagene Inc, Key Competitors 42
Trovagene Inc, Key Employees 43
Trovagene Inc, Subsidiaries 44

★海外企業調査レポート[Trovagene Inc (TROV)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cocrystal Pharma Inc (COCP)：企業の財務・戦略的SWOT分析
    Summary Cocrystal Pharma Inc (Cocrystal Pharma), formerly Biozone Pharmaceuticals Inc, a subsidiary of MusclePharm Corp, is a clinical stage biotechnology company that discovers and develops novel antiviral therapeutics. The company provides treatments for chronic viral diseases. Its pipeline produc …
  • Optiscan Imaging Limited (OIL)-医療機器分野：企業M&A・提携分析
    Summary Optiscan Imaging Limited (Optiscan) is a technology and product development company. It focuses on the development and application of microscopic imaging technologies for medical procedures. The company’s key product is ViewnVivo, a miniaturized fluorescence endo-microscope platform that bri …
  • Emgesa SA ESP-エネルギー分野：企業M&A・提携分析
    Summary Emgesa SA ESP (Emgesa), a subsidiary of Enel, is an energy utility that generates and trades electricity. The company produces power from hydro, coal, and oil and gas; and procures energy from generator and trader agents in the wholesale market. It owns thermal stations: Cartagena and Martin …
  • Schneider Electric SE (SU)-石油・ガス分野：企業M&A・提携分析
    Summary Schneider Electric SE (Schneider Electric), formerly Schneider Electric SA, is an energy management and automation company that develops related technologies and solutions for electricity distribution. Its product line comprises automation and control products, building management and securi …
  • Gilead Sciences Inc (GILD)-製薬・医療分野：企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • Stresau Laboratory, Inc.：企業の戦略・SWOT・財務情報
    Stresau Laboratory, Inc. - Strategy, SWOT and Corporate Finance Report Summary Stresau Laboratory, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • ethris GmbH-製薬・医療分野：企業M&A・提携分析
    Summary ethris GmbH (Ethris) is a biotechnology company that develops and manufactures therapeutics. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vacci …
  • Mirabilis Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Mirabilis Medical Inc (Mirabilis Medical) is a medical device company that develops a non-invasive therapeutic ultrasound platform for the treatment of uterine fibroids in women. The company offers platform that targets symptoms of uterine fibroids such as pain, abnormal bleeding, pregnancy …
  • Johnson & Johnson (JNJ)：企業の財務・戦略的SWOT分析
    Johnson & Johnson (JNJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • BioTex Inc：企業の製品パイプライン分析
    Summary BioTex Inc (BioTex) operates as a medical device company that designs, develops, manufactures and distributes electro-mechanical, optical and software based devices. The company offers sterile and non-sterile disposable products for surgical, non-surgical and interventional procedures in dia …
  • Syngene International Ltd (SYNGENE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and manufacturing organisation. The organisation offers research, development and manufacturing programs. It provides discovery chemistry, discovery biology, large molecule development, safety assessment, …
  • Ascent Solar Technologies Inc (ASTI)-エネルギー分野：企業M&A・提携分析
    Summary Ascent Solar Technologies, Inc. (Ascent solar) is a developer and manufacturer of thin-film photovoltaic modules using substrate materials. It develops products by using thin-film copper-indium-gallium- diselenide (CIGS) photovoltaic technology. The product portfolio of the company includes …
  • MonTa Biosciences ApS：製薬・医療：M&Aディール及び事業提携情報
    Summary MonTa Biosciences ApS (MonTa Biosciences) is a biotechnology company that develops and commercializes immuno-oncology therapeutics for cancer therapy. Its pipeline products include MBS2, and MBS5 used for the treatment of cancer and infectious diseases. The company’s technology is based on T …
  • Summit Midstream Partners LP (SMLP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Summit Midstream Partners LP (SMLP) is an oil and gas company that develops, owns and operates midstream energy infrastructure assets located in unconventional shale resource basins and shale formations across North America. The company operates natural gas, crude oil, and produced water gat …
  • Teijin Limited：戦略・SWOT・企業財務分析
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Renaissance Oil Corp (ROE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • Sorrento Therapeutics Inc (SRNE)：企業の財務・戦略的SWOT分析
    Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Jellagen Pty Ltd-医療機器分野：企業M&A・提携分析
    Summary Jellagen Pty Ltd (Jellagen) is a provider of medical grade collagen products. The company’s products offer medical grade collagen supplied in the form of hydragel used in wound dressing, soft tissue regeneration, tissue engineering and haemostats. Its product pipeline offer scaffolds which c …
  • Windtree Therapeutics Inc (WINT)-医療機器分野：企業M&A・提携分析
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • Qiagen Marseille SA-医療機器分野：企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆